

## ABSTRACT

There is provided means for increasing complete remission rates and shortening a period to complete remission and for achieving a synergistic effect with immunotherapy that is directed at bringing about enhanced effects from molecule-targeting therapeutic drugs. More specifically, an object is to achieve a synergistic effect by combining use of a novel immunotherapy for cancer that focuses on CTL activity, NKT activity, NK activity and -VEGF and the like, and molecule-targeting therapeutic drugs, particularly tyrosine kinase inhibitors. The present invention was accomplished based on the finding that combined use of a tyrosine kinase inhibitor and an IL-12 inducer achieves a superior synergistic effect in cancer therapy.